Blog
RSS FeedPosted by Michael Wonder on 12 May 2020
Evaluation of the impact of patient involvement in health technology assessments: a scoping review
8 May 2020 - While involving patients in health technology assessment has become increasingly common and important around the world, little ...
Posted by Michael Wonder on 12 Nov 2019
'Incredibly upsetting': breast cancer patients dealing with shortage of common drug treatment
12 November 2019 - When Tricia Smith tried to fill her prescription for tamoxifen two weeks ago, she was shocked ...
Posted by Michael Wonder on 24 Oct 2019
Women living with metastatic breast cancer in British Columbia now have public access to Kisqali
23 October 2019 - Novartis Pharmaceuticals Canada is pleased to announce that British Columbia will now reimburse Kisqali (ribociclib) for eligible ...
Posted by Michael Wonder on 10 Oct 2019
Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...
Posted by Michael Wonder on 23 Sep 2019
Health‐related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan‐Canadian Oncology Drug Review
23 September 2019 - In Canada, CADTH evaluates and makes recommendations for the reimbursement of cancer drugs. One component of ...
Posted by Michael Wonder on 20 Sep 2019
Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer
19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...
Posted by Michael Wonder on 13 Sep 2019
Medexus reports Health Quality Ontario recommends Gliolan for public reimbursement
12 September 2019 - Medexus Pharmaceuticals today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology ...
Posted by Michael Wonder on 19 Aug 2019
Quebec becomes first province to list Lonsurf (trifluridine/tipiracil) for public reimbursement for adult patients with metastatic colorectal cancer
19 August 2019 - Cancer treatment taken orally shown to extend overall survival in patients whose disease has progressed following treatment ...
Posted by Michael Wonder on 14 Aug 2019
Costing methods applied to cancer
8 August 2019 - Health care is vital in improving quality and length of life. ...
Posted by Michael Wonder on 06 Aug 2019
Cancer doctors are calling for a permanent fix to drug shortages in Canada
5 August 2019 - Three chemotherapy cancer drugs face national shortages, putting pressure on health care providers. ...
Posted by Michael Wonder on 12 Jun 2019
New drug helps extend survival rate of men with advanced prostate cancer: B.C. Cancer Agency study
10 June 2019 - At two years, advanced prostate cancer patients taking the trial drug, in addition to their standard treatment, ...
Posted by Michael Wonder on 16 Apr 2019
New genetic therapies in cancer treatment could impact benefits plans
12 April 2019 - In September 2018, Health Canada approved, for the first time, the use of a chimeric antigen ...
Posted by Michael Wonder on 23 Mar 2019
A patient’s journey with melanoma and drug coverage concerns
22 March 2019 - Living her best life with her husband Jeremy, Karen Formosa was looking forward to retiring within ...
Posted by Michael Wonder on 21 Jan 2019
Will price be a barrier to new cancer immunotherapy?
19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...
Posted by Michael Wonder on 16 Dec 2018
2019 oncology drugs in pipeline — survey
14 December 2018 - pCODR is again undertaking its periodic survey to facilitate consistent and systematic data collection from participating ...